Caplin Point Laboratories · NSE: CAPLIPOINT · BSE: 524742
Q3 FY21 results · Oct–Dec 2020
Caplin Point Laboratories reported revenue from operations of ₹123.16 crore (down 20.1% from Q3 FY20) and net profit of ₹41.48 crore (down 12.8% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a standalone basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 123.16 | 154.17 | −20.1% | 116.92 | +5.3% |
| Other income | 3.98 | 8.43 | −52.8% | 3.24 | +22.8% |
| Total income | 127.14 | 162.61 | −21.8% | 120.16 | +5.8% |
| Profit before tax | 55.31 | 60.59 | −8.7% | 53.99 | +2.4% |
| Net profit for the period | 41.48 | 47.59 | −12.8% | 41.26 | +0.5% |
| EPS, basic (₹) | 5.48 | 6.29 | −12.9% | 5.45 | +0.6% |
| Net margin (%) | 33.7 | 30.9 | 35.3 |
Standalone
- Filed with BSE
- 05 Feb 2021, 10:28 IST
- Board meeting
- 04 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE